{{Drugbox
| IUPAC_name = (''RS'')-2-[(3-Amino-2,4,6-triiodophenyl)methyl]butanoic acid
| image = iopanoic acid.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|CONS|iopanoic_acid}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number = 96-83-3
| ATC_prefix = V08
| ATC_suffix = AC06
| PubChem = 3735
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB08946
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = FE9794P71J
| KEGG = D01014
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 867
| ChemSpiderID      = 3604

<!--Chemical data-->
| C=11 | H=12 | I=3 | N=1 | O=2 
| molecular_weight = 570.93 g/mol
| smiles            = CCC(CC1=C(C(=C(C=C1I)I)N)I)C(=O)O
| StdInChI          = 1S/C11H12I3NO2/c1-2-5(11(16)17)3-6-7(12)4-8(13)10(15)9(6)14/h4-5H,2-3,15H2,1H3,(H,16,17)
| StdInChIKey       = OIRFJRBSRORBCM-UHFFFAOYSA-N
| melting_point = 162-163

}}

'''Iopanoic acid''' is an [[iodine]]-containing [[radiocontrast|radiocontrast medium]] used in [[cholecystography]]. Both iopanoic acid and [[ipodate sodium]] are potent inhibitors of [[thyroid hormone]] release from [[thyroid gland]], as well as of peripheral conversion of [[thyroxine]] (T<sub>4</sub>) to [[triiodothyronine]] (T<sub>3</sub>). These compounds inhibit 5'deiodinase (5'DID-1 and 5'DID-2) enzymes, which catalyse T<sub>4</sub>-T<sub>3</sub> conversion in the thyroid cell, liver, kidney, skeletal muscle, heart, brain, pituitary. This accounts for the dramatic improvement in both subjective and objective symptoms of [[hyperthyroidism]], particularly when they are used as an adjunctive therapy with [[thioamide]]s ([[propylthiouracil]], [[carbimazole]]). They can be used in the treatment of patients with severe [[thyrotoxicosis]] (thyroid storm) and significant morbidity (e.g., [[myocardial infarction]], or stroke) for rapid control of elevated plasma triiodothyronine concentrations.  The use of iopanoic acid for treatment of thyrotoxicosis has been discontinued in the United States.

In addition to inhibiting deiodinase enzymes, iopanoic acid is also a substrate of type 1 deiodinase. Iopanoic acid underwent monodeiodination in the presence of type 1 deiodinase in a microsomal mouse liver preparation.<ref>{{cite journal|last=Renko|first=K.|author2=Hoefig, C. S. |author3=Hiller, F. |author4=Schomburg, L. |author5= Kohrle, J. |title=Identification of Iopanoic Acid as Substrate of Type 1 Deiodinase by a Novel Nonradioactive Iodide-Release Assay|journal=Endocrinology|date=20 March 2012|volume=153|issue=5|pages=2506â€“2513|doi=10.1210/en.2011-1863 |pmid=22434082}}</ref>

== References ==
{{reflist}}

{{Contrast media}}
{{Thyroid hormone receptor modulators}}

[[Category:Radiocontrast agents]]
[[Category:Iodoarenes]]
[[Category:Carboxylic acids]]
[[Category:Anilines]]


{{pharmacology-stub}}